For patients with high-risk resectable cutaneous melanoma (stage IIB or higher), adjuvant treatment with checkpoint inhibitor immunotherapy (mechanisms demonstrated in Figure 3 and Figure 4) or BRAF/MEK targeted therapy is now the standard of care. Here, MAP2K7 is linked to cutaneous melanoma.